1st Quarter - Report

JAMES EDWARDS for CONSERVATIVES FOR PROPERTY RIGHTS

Firm
Client
Income
$60,000
Expenses
—

What was lobbied

4 issue areas, each in the filer's own words, with who lobbied on it and where.

Taxation/Internal Revenue Code TAX

S. 215/H.R. 218 (Death Tax Repeal Act) H.R. 3301 (Taxpayer Certainty and Disaster Tax Relief Act) Wealth tax Treasury Dept. Estate and Gift Taxes Regulation re Difference in the Basic Exclusion Amount H.R. 5377 (Restoring Tax Fairness for States and Localities Act) SALT deductibility cap repeal

LobbyistCovered position, as disclosed
JAMES R EDWARDS LD, Rep. Ed Bryant; LA/Press Secretary, Rep. John Duncan; Special Assistant, Senate Judiciary Committee

Contacted: HOUSE OF REPRESENTATIVES; Patent & Trademark Office (PTO); Executive Office of the President (EOP); Food & Drug Administration (FDA); Council on Environmental Quality (CEQ); U.S. Trade Representative (USTR); SENATE; Justice, Dept of (DOJ)

Bills named: H.R. 218 (116th), S. 215 (116th), H.R. 5377 (116th), H.R. 3301 (116th)

Copyright/Patent/Trademark CPT

S. 2082/H.R. 3666 (STRONGER Patents Act) Trade-related intellectual property policy/practices/encroachment by foreign countries/companies against U.S. competitiveness interests - China, Committee on Foreign Investment in the United States review of Chinese acquisitions and joint ventures, United States-Mexico-Canada Agreement IP chapter, International Trade Commission exclusion of U.S. patent-infringing imports, ITC baseband chip set patent infringement remedy, intellectual property exclusivity and protections in trade agreements Piracy of online and streaming copyrighted content Compulsory licensing - S. 377/H.R. 1046 (Medicare Negotiation and Competitive Licensing Act), S. 102/H.R. 465 (Prescription Drug Price Relief Act), S. 977 (Transparent Drug Pricing Act) NIST Return on Investment Initiative for Unleashing American Innovation S. 344/H.R. 990 (Hatch-Waxman Integrity Act) FTC/patent licensing as exclusive property right Bayh-Dole Act/technology transfer, march-in rights Procedural and evidentiary standards used at Patent Trial and Appeal Board PTO patentable subject matter eligibility guidance Section 101 patentable subject matter reform Injunctive relief from willful infringement DOJ-DOC withdrawal of 2013 Policy Statement on Remedies for Standards-Essential Patents Subject to Voluntary F/RAND Commitments S. 1273/H.R. 2426 (Copyright Alternative in Small-Claims Enforcement (CASE) Act) S. 1416 (Affordable Prescriptions for Patients Act) Obviousness/No Combination Drug Patents Act H.R. 4398/H.R. 5133 (Affordable Prescriptions for Patients Through Promoting Competition Act) H.R. 3991 (Affordable Prescriptions for Patients Through Improvements to Patent Litigation Act) H.R. 5478 (Inventor Rights Act) Patent licensing/standards-essential patents/U.S. technological leadership in 5G and other technologies/economic and national security implications DOJ-PTO-NIST 2019 revised Joint Statement on Remedies for Standards-Essential Patents Subject to Voluntary F/RAND Commitments Efficient infringement Digital Millennium Copyright Act modernization

LobbyistCovered position, as disclosed
JAMES R EDWARDS LD, Rep. Ed Bryant; LA/Press Secretary, Rep. John Duncan; Special Assistant, Senate Judiciary Committee

Contacted: Council on Environmental Quality (CEQ); Food & Drug Administration (FDA); U.S. Trade Representative (USTR); Executive Office of the President (EOP); SENATE; Patent & Trademark Office (PTO); Justice, Dept of (DOJ); HOUSE OF REPRESENTATIVES

Bills named: S. 2082 (116th), S. 1416 (116th), H.R. 5133 (116th), H.R. 3991 (116th), S. 977 (116th), S. 102 (116th), S. 344 (116th), S. 1273 (116th), H.R. 4398 (116th), H.R. 2426 (116th), H.R. 990 (116th), H.R. 1046 (116th), H.R. 5478 (116th), S. 377 (116th), H.R. 465 (116th), H.R. 3666 (116th)

Medicare/Medicaid MMM

Proposed International Pricing Index (IPI) payment model for drugs administered under Medicare Part B S. 377/H.R. 1046 (Medicare Negotiation and Competitive Licensing Act) Reform of drug manufacturer rebates to third parties (e.g., pharmaceutical benefits managers, insurers) Proposed binding arbitration for enacting government price controls under Medicare Part D Inflationary penalty as government price controls in Medicare Part D/S. 2543 (Prescription Drug Pricing Reduction Act) S. 1129/H.R. 1384 (Medicare for All Act) Single-payer health care Government price controls on health care products, services, providers, payers H.R. 3 (Elijah E. Cummings Lower Drug Costs Now Act) drug price controls through international reference pricing, direct federal price dictation, confiscatory penalty on the most innovative medicines Importation of Prescription Drugs Proposed Rule

LobbyistCovered position, as disclosed
JAMES R EDWARDS LD, Rep. Ed Bryant; LA/Press Secretary, Rep. John Duncan; Special Assistant, Senate Judiciary Committee

Contacted: SENATE; U.S. Trade Representative (USTR); Food & Drug Administration (FDA); Council on Environmental Quality (CEQ); Justice, Dept of (DOJ); Executive Office of the President (EOP); HOUSE OF REPRESENTATIVES; Patent & Trademark Office (PTO)

Bills named: S. 1129 (116th), S. 2543 (116th), H.R. 3 (116th), S. 377 (116th), H.R. 1046 (116th), H.R. 1384 (116th)

Real Estate/Land Use/Conservation RES

Waters of the United States rule repeal - by regulatory reform of WOTUS, in appropriations S.Res. 59/H.Res. 109 (Green New Deal resolution calling for the socialistic federal takeover of private property of American citizens and organizations and extinction of any meaningful private property rights in the United States) Land management/acquisition Public access to federally owned lands for sports, recreation, mining, commercial use Social Costs of Carbon project termination EPA regulatory and permitting reform Draft Environmental Impact Statement for the Pebble Mine Project H.R. 1373 (Grand Canyon Centennial Protection Act) H.R. 2181 (Chaco Cultural Heritage Area Protection Act) H.R. 3405 (Uranium Classification Act) Methane Rule reform Regulatory fairness and due process/National Environmental Policy Act reform

LobbyistCovered position, as disclosed
JAMES R EDWARDS LD, Rep. Ed Bryant; LA/Press Secretary, Rep. John Duncan; Special Assistant, Senate Judiciary Committee

Contacted: Justice, Dept of (DOJ); Council on Environmental Quality (CEQ); Executive Office of the President (EOP); Patent & Trademark Office (PTO); HOUSE OF REPRESENTATIVES; SENATE; Food & Drug Administration (FDA); U.S. Trade Representative (USTR)

Bills named: S.Res. 59 (116th), H.R. 2181 (116th), H.Res. 109 (116th), H.R. 3405 (116th), H.R. 1373 (116th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.